Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia

Cancer Cell

Volumn 28, Issue 1, 2015, Pages 114-128

  Shojaee, Seyedmehdi ^a   Caeser, Rebecca ^a,k   Buchner, Maike ^a   Park, Eugene ^k   Swaminathan, Srividya ^a   Hurtz, Christian ^a   Geng, Huimin ^a   Chan, LaiN ^a   Klemm, Lars ^a   Hofmann, Wolf Karsten ^b   Qiu, YiHua ^c   Zhang, Nianxiang ^c   Coombes, KevinR ^c   Paietta, Elisabeth ^d   Molkentin, Jeffery ^e   Koeffler, H Phillip ^f,g   Willman, CherylL ^h   Hunger, StephenP ⁱ   Melnick, Ari ^j   Kornblau, StevenM ^c   Müschen, Markus ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZYLIDENE 3 (CYCLOHEXYLAMINO) 1 INDANONE; ARF PROTEIN; ATM PROTEIN; BETA ACTIN; CHECKPOINT KINASE 2; DUAL SPECIFICITY PHOSPHATASE 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DUSP6 PROTEIN, MOUSE; ETV5 PROTEIN, MOUSE; HOST CELL FACTOR C1; MEMBRANE PROTEIN; MOLECULAR LIBRARY; SIGNAL PEPTIDE; SPRY2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CELL CLONE; CELL DEATH; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG SELECTIVITY; DUSP6 GENE; ETV5 GENE; GENE ACTIVATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPRY2 GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR GENETICS; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY; PROGNOSIS; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DUAL SPECIFICITY PHOSPHATASE 6; HOST CELL FACTOR C1; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS;

EID: 84937523707     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.05.008     Document Type: Article

References (35)

1. Bhojwani D., Pui C.H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013, 14:e205-e217.
2. Chen C., Ouyang W., Grigura V., Zhou Q., Carnes K., Lim H., Zhao G.Q., Arber S., Kurpios N., Murphy T.L., et al. ERM is required for transcriptional control of the spermatogonial stem cell niche. Nature 2005, 436:1030-1034.
3. Chi P., Chen Y., Zhang L., Guo X., Wongvipat J., Shamu T., Fletcher J.A., Dewell S., Maki R.G., Zheng D., et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010, 467:849-853.
4. Cortes J.E., Kim D.W., Pinilla-Ibarz J., le Coutre P., Paquette R., Chuah C., Nicolini F.E., Apperley J.F., Khoury H.J., Talpaz M., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N.Engl. J. Med. 2013, 369:1783-1796. PACE Investigators.
5. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., Hollstein P.E., MacCollin M., Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
6. Dang P.M.-C., Stensballe A., Boussetta T., Raad H., Dewas C., Kroviarski Y., Hayem G., Jensen O.N., Gougerot-Pocidalo M.-A., El-Benna J. A specific p47phox -serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J.Clin. Invest. 2006, 116:2033-2043.
7. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N.Engl. J. Med. 2001, 344:1038-1042.
8. Fielding A.K. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2010, 116:3409-3417.
9. Frank M.J., Dawson D.W., Bensinger S.J., Hong J.S., Knosp W.M., Xu L., Balatoni C.E., Allen E.L., Shen R.R., Bar-Sagi D., et al. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood 2009, 113:2478-2487.
10. Fuchs S.Y., Adler V., Pincus M.R., Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. USA 1998, 95:10541-10546.
11. Golding S.E., Rosenberg E., Neill S., Dent P., Povirk L.F., Valerie K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 2007, 67:1046-1053.
12. Hanafusa H., Torii S., Yasunaga T., Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 2002, 4:850-858.
13. Hantschel O., Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2004, 5:33-44.
14. Hollenhorst P.C., Ferris M.W., Hull M.A., Chae H., Kim S., Graves B.J. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev. 2011, 25:2147-2157.
15. Irving J., Matheson E., Minto L., Blair H., Case M., Halsey C., Swidenbank I., Ponthan F., Kirschner-Schwabe R., Groeneveld-Krentz S., et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014, 124:3420-3430.
16. Limnander A., Depeille P., Freedman T.S., Liou J., Leitges M., Kurosaki T., Roose J.P., Weiss A. STIM1, PKC-δ and RasGRP set a threshold for proapoptotic Erk signaling during B cell development. Nat. Immunol. 2011, 12:425-433.
17. Maillet M., Purcell N.H., Sargent M.A., York A.J., Bueno O.F., Molkentin J.D. DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J.Biol. Chem. 2008, 283:31246-31255.
18. E600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
19. Molina G., Vogt A., Bakan A., Dai W., Queiroz de Oliveira P., Znosko W., Smithgall T.E., Bahar I., Lazo J.S., Day B.W., Tsang M. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat. Chem. Biol. 2009, 5:680-687.
20. Murphy S.L., Xu J., Kochanek K.D. Deaths: Final data for 2010. National vital statistics reports from the U.S. Department of Health and Human Services, Natl. Vital Stat. Rep. 2013, 61:1-117.
21. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
22. Roberts K.G., Morin R.D., Zhang J., Hirst M., Zhao Y., Su X., Chen S.-C., Payne-Turner D., Churchman M.L., Harvey R.C., et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012, 22:153-166.
23. Roberts K.G., Li Y., Payne-Turner D., Harvey R.C., Yang Y., Pei D., McCastlain K., Ding L., Lu C., Song G., et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N.Engl. J. Med. 2014, 371:1005-1015.
24. Schutzman J.L., Martin G.R. Sprouty genes function in suppression of prostate tumorigenesis. Proc. Natl. Acad. Sci. USA 2012, 109:20023-20028.
25. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
26. Shaw A.T., Meissner A., Dowdle J.A., Crowley D., Magendantz M., Ouyang C., Parisi T., Rajagopal J., Blank L.J., Bronson R.T., et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev. 2007, 21:694-707.
27. Shim K., Minowada G., Coling D.E., Martin G.R. Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev. Cell 2005, 8:553-564.
28. Tanoue T., Adachi M., Moriguchi T., Nishida E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2000, 2:110-116.
29. Vogt A., Cooley K.A., Brisson M., Tarpley M.G., Wipf P., Lazo J.S. Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem. Biol. 2003, 10:733-742.
30. Voncken J.W., Morris C., Pattengale P., Dennert G., Kikly C., Groffen J., Heisterkamp N. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice. Blood 1992, 79:1029-1036.
31. Wong V.C.L., Chen H., Ko J.M.Y., Chan K.W., Chan Y.P., Law S., Chua D., Kwong D.L.-W., Lung H.L., Srivastava G., et al. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int. J. Cancer 2012, 130:83-95.
32. Xu S., Furukawa T., Kanai N., Sunamura M., Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J.Hum. Genet. 2005, 50:159-167.
33. Zabriskie M.S., Eide C.A., Tantravahi S.K., Vellore N.A., Estrada J., Nicolini F.E., Khoury H.J., Larson R.A., Konopleva M., Cortes J.E., et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014, 26:428-442.
34. Zhang J., Mullighan C.G., Harvey R.C., Wu G., Chen X., Edmonson M., Buetow K.H., Carroll W.L., Chen I.-M., Devidas M., et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011, 118:3080-3087.
35. Znosko W.A., Yu S., Thomas K., Molina G.A., Li C., Tsang W., Dawid I.B., Moon A.M., Tsang M. Overlapping functions of Pea3 ETS transcription factors in FGF signaling during zebrafish development. Dev. Biol. 2010, 342:11-25.